AI Article Synopsis
- Psoriasis (PsO) and psoriatic arthritis (PsA) are often not treated adequately, and a multidisciplinary approach is needed, especially with the emergence of anti-TNF biosimilars like adalimumab.
- A panel of 36 Italian dermatologists and rheumatologists used the Delphi Method to reach a consensus on how to effectively manage PsO and PsA with adalimumab, ultimately showing strong support for its efficacy and long-term use.
- The study concluded that adalimumab is highly recommended as a first-line treatment for specific cases, such as concurrent conditions like inflammatory bowel disease or uveitis, and serves as a solid alternative after other treatments fail.
Article Abstract
Background And Objectives: Psoriasis (PsO) and psoriatic arthritis (PsA) are often undertreated and require a multidisciplinary approach. In recent years, patent expiration has allowed the introduction of tumor necrosis factor inhibitor (anti-TNF) biosimilars, which have stimulated a significant increase in the use of biological therapies. This article reports the findings of a multidisciplinary approach to achieve a consensus on the use of adalimumab in patients with PsO or PsA.
Methods: A voting panel of 36 Italian dermatologists and rheumatologists were chosen by eight Italian clinicians (the Board), to provide a consensus on the real-world management of PsO and PsA with adalimumab using the Delphi Method, comprising three survey rounds. Twelve statements were defined by the Board and submitted to the panel (rating scale 1-7).
Results: Clinicians reached a wide consensus on the effectiveness (score 6-7: 67%) and long-term efficacy (6-7: 100%) of adalimumab in all clinical forms of PsO and PsA, including pediatric patients (6-7: 85%). Considering cost-effectiveness and safety, adalimumab is suggested as a first-line treatment in patients with enthesitis, predominant peripheral arthritis, axial involvement or associated inflammatory bowel disease (IBD) or uveitis. Adalimumab can be also considered after failure of etanercept (6-7: 94%).
Conclusion: Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985702 | PMC |
| http://dx.doi.org/10.1515/rir-2024-0006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transforming Cancer Classification: The Role of Advanced Gene Selection.
Diagnostics (Basel)
November 2024
Department of Industrial Engineering and Management, Yuan Ze University, Taoyuan City 320315, Taiwan.
Accurate classification in cancer research is vital for devising effective treatment strategies. Precise cancer classification depends significantly on selecting the most informative genes from high-dimensional datasets, a task made complex by the extensive data involved. This study introduces the Two-stage MI-PSA Gene Selection algorithm, a novel approach designed to enhance cancer classification accuracy through robust gene selection methods.
View Article and Find Full Text PDFEvaluation of the "Multivariable Psoriatic Arthritis Risk Estimation Tool" in a Cohort of Patients with Psoriasis: Preliminary Results of a Prospective Observational Study.
Rheumatol Ther
December 2024
Academic Rheumatology Unit and MoRhe Project, Dipartimento di Medicina e Scienze della Salute "Vincenzo Tiberio", Università degli Studi del Molise, Via Giovanni Paolo II, C/da Tappino, 86100, Campobasso, Italy.
Introduction: An intriguing aspect that emerged in recent years is the transition phase from psoriasis (PsO) to psoriatic arthritis (PsA). The PRESTO instrument allows estimating a patient's risk of developing PsA based on a few clinical items. The aim of this study was to apply and evaluate the performance of the PRESTO tool in a cohort of patients with PsO.
View Article and Find Full Text PDFPost-Marketing Safety of Ustekinumab Based on 14-Year Follow-Up in Danish National Patient Data.
Pharmacoepidemiol Drug Saf
December 2024
Department of Pediatrics and Adolescent Medicine, Danish National University Hospital "Rigshospitalet", Copenhagen, Denmark.
Article Synopsis
- This 14-year cohort study investigated the long-term safety of ustekinumab, a biologic treatment for psoriasis, using data from Danish national registers.
- The study compared safety outcomes like cancers and serious infections in ustekinumab users against patients receiving other systemic treatments, including non-biologics and various biologic therapies.
- Results showed that ustekinumab is generally safe, with no major safety concerns identified, and users were younger and had different gender distributions compared to users of other treatments.
Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey.
J Psoriasis Psoriatic Arthritis
October 2024
University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Despite advancements in the treatment landscape for psoriasis (PsO) and psoriatic arthritis (PsA), some patients may not achieve the desired disease improvement due to undertreatment. Understanding patient perspectives on treatment expectations can inform patient-centered decisions and enhance treatment satisfaction.
Objective: To describe patient-identified treatment goals and expectations for managing psoriatic disease.
Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium.
Ann Rheum Dis
November 2024
Department of Medicine and Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Objectives: To identify phenotype clusters and their trajectories in psoriatic arthritis (PsA) and examine the association of the clusters with treatment response in a real-world setting.
Methods: In the multicentre PsA Research Consortium (PARC) study, we applied factor analysis of mixed data to reduce dimensionality and collinearity, followed by hierarchical clustering on principal components. We then evaluated the transition of PsA clusters and their response to new immunomodulatory therapy and tumour necrosis factor inhibitor (TNFi).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!